Grants

Educationcommunity developmentHealth+1

Free to search & build · $99 one-time to unlock the application pack · No subscription

Nevada Division of Environmental Protection Water Pollution Control Grants

Nevada Division of Environmental Protection

NDEP provides grants to municipalities and wastewater agencies for water pollution control projects, including wastewater treatment facility upgrades, nonpoint source pollution reduction, and watershed protection across Nevada.

$50K – $2M

environmentinfrastructureHealth

Free to search & build · $99 one-time to unlock the application pack · No subscription

Nevada GOED Business Incentives

Nevada Governor's Office of Economic Development

Provides transferable tax credits, abatements, and the Knowledge Fund for technology commercialization and startup support.

$25K – $1.5M

economic developmenttechnologytax incentives

Free to search & build · $99 one-time to unlock the application pack · No subscription

Nevada GOED Catalyst Fund

Governor's Office of Economic Development

The Catalyst Fund provides grants and gap financing to Nevada startups and early-stage companies in diversified industries, supporting business growth, job creation, and economic diversification in targeted sectors.

$25K – $500K

Business Developmenttechnologyworkforce

Free to search & build · $99 one-time to unlock the application pack · No subscription

Nevada GOED Community Development Block Grant Program

Governor's Office of Economic Development

Nevada's state-administered CDBG program provides grants to non-entitlement communities for public works improvements, housing rehabilitation, economic development activities, and public services benefiting low- and moderate-income residents.

$50K – $500K

Community DevelopmentinfrastructureHousing

Free to search & build · $99 one-time to unlock the application pack · No subscription

Nevada GOED Knowledge Fund

Governor's Office of Economic Development

The Knowledge Fund supports applied research and development at Nevada's higher education institutions, funding projects that align with targeted industry sectors and drive innovation, commercialization, and economic diversification.

$50K – $500K

researchtechnologyBusiness Development

Free to search & build · $99 one-time to unlock the application pack · No subscription

Nevada Housing Division Account for Affordable Housing Trust Fund

Nevada Housing Division

The Account for Affordable Housing Trust Fund provides grants to nonprofits and government entities for projects that increase the supply of affordable housing in Nevada, including transitional housing and housing for special needs populations.

$25K – $500K

HousingEquity & AccessHealth

Free to search & build · $99 one-time to unlock the application pack · No subscription

Nevada Housing Division HOME Investment Partnerships

Nevada Housing Division

The Nevada Housing Division administers the HOME program providing grants and loans for affordable housing development, rehabilitation, and tenant-based rental assistance programs serving low-income households across Nevada.

$50K – $1M

HousingCommunity DevelopmentEquity & Access

Free to search & build · $99 one-time to unlock the application pack · No subscription

Nevada Humanities Council Grants

Nevada Humanities Council

Grants for humanities programming including lectures, exhibitions, oral history, documentary, and public humanities projects in Nevada. Funded by NEH.

$500 – $8K

EducationArts & CultureCommunity Development

Free to search & build · $99 one-time to unlock the application pack · No subscription

NEW - Air Force Installation and Mission Support Center (AFIMSC) Streamlining Procurement for Effective Execution & Delivery (SPEED) Commercial Solutions Opening (CSO)

DEPT OF DEFENSE.DEPT OF THE AIR FORCE.AIR FORCE MATERIEL COMMAND.AF INSTALLATION & MISSION SUPPORT CENTER.FA8903 772 ESS PK

NEW - Air Force Installation and Mission Support Center (AFIMSC) Streamlining Procurement for Effective Execution & Delivery (SPEED) Commercial Solutions Opening (CSO)

2030-08-29

general

Free to search & build · $99 one-time to unlock the application pack · No subscription

New abilities in over-the-horizon sensing

European Commission - EDF

New abilities in over-the-horizon sensing. Call: Development actions implemented via lump sum grants targeting disruptive technologies for defence. Programme: EDF. Open call from the EU Funding & Tenders Portal.

$50K

2026-09-29

public_safety

Free to search & build · $99 one-time to unlock the application pack · No subscription

New approach methodologies using stem cell morphogenesis models for preclinical developmental toxicity screening

NIEHS - National Institute of Environmental Health Sciences

Proposal Abstract Traditionally, live animals have been used to assess the toxicity of candidate chemicals in pharmaceutical drug development. However, animal tests are increasingly scrutinized for being time- consuming, costly, and ethically challenging. This has driven demand for non-animal alternative tests, or new approach methodologies (NAMs). The recent FDA Modernization Act 2.0 supports this shift by permitting the adoption of validated NAMs in place of animal tests for safety assessments and regulatory approval of human trials. NAMs can serve as first-tier screening tools to identify potentially toxic drugs, allowing only those with no apparent toxicity to proceed to animal testing if necessary. This tiered approach could significantly reduce live animal use. To achieve this goal, rigorous validation of individual NAMs according to international standards is essential to ensure regulatory acceptance. The proposed project aims to establish validated NAMs for developmental and reproductive toxicity (DART) assessment using morphogenesis models derived from pluripotent stem cells. My lab has previously developed these morphogenesis models from mouse and human stem cells, which recapitulate key morphological and molecular events of early embryogenesis in vitro. In published studies, we showed that these models exhibit significant morphological and gene expression changes in response to chemicals known to cause birth defects or miscarriages. To validate these models as NAMs for DART assessment, we will apply the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) guideline, which provides a list of reference drugs with comprehensive in vivo toxicokinetics data, such as rodent plasma concentrations linked to embryotoxicity and non-embryotoxicity. These data can serve as benchmarks to evaluate the effectiveness of NAMs in predicting embryotoxic drug concentrations in alignment with in vivo results. To accomplish our objective, we propose three Specific Aims. Aim 1 is to examine the impact of embryotoxic drug exposures on the gene expression profiles in the mouse morphogenesis model. Aim 2 is to enhance detection capabilities through molecular augmentation of the mouse morphogenesis model. Aim 3 is to examine the response of a human stem cell-based morphogenesis model in reference to available rodent toxicokinetics data. This project is significant in its potential to establish validated NAMs as non-animal alternatives for preclinical DART assessments. It is innovative in its use of advanced stem cell technology to model embryological processes, facilitating precise concentration-specific analyses aligned with high international standards.

Up to $157K

2028-04-08

Free to search & build · $99 one-time to unlock the application pack · No subscription

New Approaches for Measuring Brain Changes Across Longer Timespans (R01 Clinical Trial Optional)

National Institutes of Health

The purpose of this funding opportunity is to encourage multidisciplinary investigators to develop new approaches or apply existing approaches in novel ways to measure brain activity, connectivity, genomics, or other aspects across the age spectrum of neurodevelopment. The overarching goal is to extend our understanding of brain development and aging, including studies of the neurodevelopmental origins of later health and disease. Research can include healthy human participants of any age, specific clinical groups such as those with cognitive, motor, or affective regulation challenges, and/or animal research on these domains of function. The studies can focus on longitudinal neuroanatomical or functional changes at any level, including genetics/genomics, single cells, connectomics, neural population activity patterns, and others. This funding opportunity is intended to encourage technological and conceptual innovation to improve repeated measures across longer epochs of the lifespan, to better predict outcomes at later ages.

2027-05-07

Education

Free to search & build · $99 one-time to unlock the application pack · No subscription

New Approaches for Measuring Brain Changes Across Longer Timespans (R01 Clinical Trial Optional)

income_security_and_social_servicesEducationHealth

National Institutes of Health

2027-05-07

Free to search & build · $99 one-time to unlock the application pack · No subscription

New Approaches for Measuring Brain Changes Across Longer Timespans (R21 Clinical Trial Optional)

National Institutes of Health

The purpose of this funding opportunity is to encourage multidisciplinary investigators to submit applications developing exploratory, highly novel new approaches, or innovative applications of existing approaches to measure brain activity, connectivity, genomics, or other aspects across the age spectrum of neurodevelopment. The overarching goal is to extend our understanding of brain development and aging, including studies of the neurodevelopmental origins of later health and disease, by improving repeated measures across longer epochs of the lifespan to better predict outcomes at later ages. . Research can include healthy human participants of any age, specific clinical groups such those with cognitive, motor, or affective regulation challenges, and/or animal research on these domains of function. The studies can focus on longitudinal neuroanatomical or functional changes at any level, including genetics/genomics, single cells, connectomics, neural population activity patterns, and others. This funding opportunity is intended to encourage technological and conceptual innovation through this high risk, high reward funding mechanism to develop highly innovative ideas that either lack preliminary data or need additional preliminary data

2027-05-07

Education

Free to search & build · $99 one-time to unlock the application pack · No subscription

New Approaches to Arrhythmia Detection and Treatment (SBIR [R43/R44])

National Institutes of Health

-This FOA will utilize the SBIR (R43/R44) grant mechanisms for Phase I, Phase II, and Fast-Track applications and runs in parallel with a FOA of identical scientific scope, PA-07-031, that solicits applications under the Small Business Technology Transfer (STTR) (R41/R42) grant mechanisms. -Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications. -Eligible Organizations: Only United States SBCs are eligible to submit SBIR applications. A SBC is one that, on the date of award for both Phase I and Phase II funding agreements, meets ALL of the criteria as described in Section III.

rolling

Healthhealthcare

Free to search & build · $99 one-time to unlock the application pack · No subscription

New Approaches to Arrhythmia Detection and Treatment (STTR [R41/R42])

National Institutes of Health

-This FOA will utilize the STTR (R41/R42) grant mechanisms for Phase I, Phase II, and Fast-Track applications and runs in parallel with a FOA of identical scientific scope, PA-07-032, that solicits applications under the Small Business Innovation Research (SBIR) (R43/R44) grant mechanisms. -Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications. -Eligible Organizations: Only United States SBCs are eligible to submit STTR applications. A SBC is one that, on the date of award for both Phase I and Phase II funding agreements, meets ALL of the criteria as described in Section III.

rolling

Healthhealthcare

Free to search & build · $99 one-time to unlock the application pack · No subscription

New approaches to the pathophysiology, diagnosis and management of heparin-induced thrombocytopenia

NHLBI - National Heart Lung and Blood Institute

PROJECT SUMMARY/ABSTRACT Heparin-induced thrombocytopenia (HIT) is a severe, antibody (ab)-mediated prothrombotic syndrome with high morbidity and mortality. The biochemical basis of the distinction between “pathogenic” platelet-activating antibodies and “benign” non-activating HIT antibodies is not well understood. This results in significant diagnostic challenges and in excessive use of non-heparin alternative anticoagulation that have worse bleeding profiles than heparin. Outcomes in HIT are suboptimal despite current therapy with direct thrombin inhibitors: One-third of affected patients develop thrombosis and one in ten patients dies. The proposed studies will explore key unanswered questions in areas of HIT pathophysiology, diagnosis, and treatment. For Aim 1, we hypothesize the existence of multiple functional classes of HIT antibodies: (1) Pathogenic antibodies that recognize PF4-treated platelets with or without reactivity to PF4-heparin complexes, and (2) Benign abs that recognize PF4-heparin but not platelets treated with PF4. We will identify and characterize these antibody classes by chromatography-based isolation from patient samples and will generate novel HIT monoclonal antibodies in each of these functional classes. Generated monoclonal antibodies will be tested for pathogenicity in a HIT mouse model and results will be correlated with their serologic characteristics. Obtaining and processing normal donor platelets is a major challenge that limits the availability of functional “gold standard” testing in HIT. In Aim 2, we will develop a rapid HIT diagnostic test using the patient’s own platelets treated with PF4/heparin. This will facilitate “in-hospital” HIT diagnosis leading to early detection of this condition. Currently used non-heparin alternative anticoagulants do not address the most proximal event in HIT: Activation of platelets by HIT antibodies. Given this, breakthrough thrombosis is frequently seen in patients under treatment and so is unintended bleeding caused by the potent non-heparin anticoagulants used. In Aim 3, we will use platelet-derived and synthetic chondroitin sulfates of various sulfation levels and saccharide lengths to evaluate their ability to inhibit HIT-antibody mediated platelet activation in vitro and to ameliorate thrombocytopenia in a HIT murine model. In Aim 1, we expect to successfully separate and characterize multiple functional classes of HIT antibodies which will suggest new ways to selectively detect only the pathogenic ones. Developing and optimizing a diagnostic method using the patient’s own platelets in Aim 2 will transform platelet-activation based HIT testing by moving it from the reference laboratory environment to the in-hospital setting. Finally, studies described in Aim 3 will introduce a new class of therapeutics in HIT, chondroitin sulfates, that will prevent thrombosis, but unlike current therapies, will not increase the risk of bleeding. In summary, we anticipate that all three aims of this proposal will lead to a significant impact on pathophysiology, diagnosis, and treatment of HIT.

Up to $249K

2026-07-31

Free to search & build · $99 one-time to unlock the application pack · No subscription

New Beginning for Tribal Students Program

Agriculturerural development

National Institute of Food and Agriculture

The purpose of the NBTS grant program, Assistance Listing 10.527, is to increase the retention and graduation rate of Tribal students attending 1994, 1862, and 1890 Land-grant Institutions. The primary goals and objectives of the program are for Land-grant Colleges or Universities to use NBTS funding to support Tribal students through all the following, but not limited to: recruiting; tuition and related fees; experiential learning; student services, including tutoring; counseling; academic advising; and other student services that would increase the retention and graduation rate of Tribal students enrolled at Land-grant Colleges or Universities.

$250K – $500K

2026-07-02

Free to search & build · $99 one-time to unlock the application pack · No subscription

New Brunswick Arts Board (artsnb)

New Brunswick Arts Board

artsnb provides grants to professional artists in New Brunswick for creation, production, and career development across all disciplines.

$1K – $50K

artsculture

Free to search & build · $99 one-time to unlock the application pack · No subscription

New Brunswick Innovation Foundation (NBIF)

New Brunswick Innovation Foundation

NBIF supports innovation and research commercialization in New Brunswick through grants to startups, researchers, and R&D projects.

$10K – $500K

innovationresearchstartups

Free to search & build · $99 one-time to unlock the application pack · No subscription

New chemical tools for the design of next generation antibody drug conjugates

NIGMS - National Institute of General Medical Sciences

Project summary Over the past decade, the clinical and societal impact of antibody-drug conjugate (ADC) technology has grown rapidly, with a notable increase in approved drugs and sales. ADCs utilize an antibody "delivery system" to bind to specific cells, releasing a cytotoxic payload upon lysosomal degradation. However, the field faces many significant challenges, including a lack of diverse linker technologies for payloads without an amine handle, few useful payloads beyond traditional cytotoxic agents, and the lack of chemistry that can rapidly explore dual-payload ADC designs. Our team has had a significant impact in these areas over the past 5 years, and is poised to have an even greater impact over the next 5 years. Herein, we propose three primary focus areas. In focus area #1, we will design new self-immolative spacers that allow the release of payloads that do not contain amine handles. Building on our recently published “GlyPro” self- immolative spacer, we will generate linkers that spontaneously release sulfonamides, ureas, carbamates, and hydroxamates. In focus area #2, we will build on our recently patented “dual payload ADC” designs to systematically look for synergistic combinations of payloads that impart unexpected activity. Our 2-step approach for the preparation of dual payload ADCs allows us to rapidly “mix and match” payloads in order to identify unexpected (or hypothesized) combinations that impart unique properties that either payload alone is incapable of achieving. Finally, in focus area #3, instead of delivering a traditional cytotoxic payload, we will design ADCs that deliver an organic-metallic catalyst. We envision a next generation of ADCs that do not deliver a “payload”, but rather deliver a new function to antigen-expressing cells. These “mechanized antibodies” may be useful for diverse applications including detoxification, anti- inflammatory therapeutics, antibody-directed prodrug activation, and even biomaterials. Together, advancements in these three focus areas will result in new ADC designs that will have a broad impact on targeted therapeutic agents in a variety of disease states.

Up to $551K

2031-03-31

Free to search & build · $99 one-time to unlock the application pack · No subscription

New Cobalt-mediated Methods for the Synthesis of Bioactive Triterpenoid Natural Products

NIGMS - National Institute of General Medical Sciences

Project Summary: The development of new, concise, and modular approaches toward physiologically important natural products that are synthetically flexible and amenable to late-stage modification is important for accessing new lead compounds and novel structural motifs for investigation as therapeutics to treat human disease. Provided that from 1981-2020 roughly 65% of all FDA approved drugs were influenced by natural products research, the unique molecular scaffolds found in nature are excellent starting points for the discovery of new lead therapeutics. While there are many factors to consider when developing a lead compound, structural complexity has become an increasingly important factor for clinical success in recent years. This work will advance new operationally-simple catalytic protocols employing bench-stable cobalt(III) complexes to build synthetically useful motifs through carbon-carbon bond formation reactions including carbonyl additions and allylboration reactions that are high utility for the synthesis of biologically relevant natural products, agrochemicals, and pharmaceuticals. The methods advanced in this work will contribute fundamental knowledge on the reactivity of first-row transition metal catalysts to help facilitate their use in new, cost-effective, and safer chemical processes. The utility and enabling power of the protocols developed with cobalt(III)-based catalysts in this work will be demonstrated through applications in the total synthesis biologically relevant triterpenoid natural products. This will lead to the first total synthesis of the sodwanones A-C and sodwanone H, which exhibits 2 nM nanomolar activity against A549 lung cancer cell lines and has the potential to serve as a lead compound for further biochemical investigations. The newly prepared compounds have a high potential to serve as a new class of antibiotics and sporicidal agents against C. difficile providing a new treatment for this common hospital acquired infection, thereby having a direct impact in solving an unmet challenge in healthcare. The pursuit of these aims will provide and expand research and training opportunities for 8 undergraduate students and one graduate student at Old Dominion University. Student trainees will develop important skillsets through cross-training in synthetic method development, total synthesis, organometallic chemistry, computational chemistry, medicinal chemistry, and biochemistry.

Up to $580K

2029-05-31